Compare BridgeBio Pharma Inc (BBIO) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs SoundHound AI Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while SoundHound AI Inc trades at $7.44 (market cap $3.25B). The key difference: BridgeBio Pharma Inc is far larger — about 5.1× SoundHound AI Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | SOUN | |
|---|---|---|
Market Cap | $16.61B | $3.25B |
Sector | Health | Technology |
52-Week High | $90.17 | $21.40 |
52-Week Low | $47.29 | $5.70 |
Enterprise Value | $18.16B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
SoundHound AI (SOUN) trades at $8.02, up 13.28% today, showing strong momentum after beating Q2 2026 earnings expectations. The stock maintains a bullish technical signal with support at $7 and resistance at $9. Revenue grew 45% last quarter to $61.9M, though the company remains unprofitable with a -67.45% net margin. Analyst consensus is strongly bullish with 75% buy ratings and an $8.50 price target.
SOUN offers growth potential through its OASYS platform expansion and enterprise adoption, but faces significant execution risks from persistent losses, cash burn, and premium valuation. The stock's near-term trajectory depends on continued revenue acceleration and path to profitability. High valuation multiples and negative cash flow present challenges despite strong analyst support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
